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Abstract







With this thesis I hope to broaden my knowledge about the scientific field of neurotoxicology and to learn more about the scientific progresses within this field. The general subject of this thesis is Parkinson's disease. The reason why I am interested in this disease is that I came in touch with this disease at a very young age. My best friends’ mother was diagnosed with PD when I was just about eight years old and heard that there was/is nothing medical science could do about the disease. My friends’ mother would not live very long. I thought it was not fair to just wait until her symptoms went so bad that she eventually could not move anymore or even die at a very young age. Now I'm almost 25 years old and I'm still seeing my friends’ mothers once in a while because she's living about two blocks away from me. I admire her because she is still pretty mobile and even passing me by on her bicycle. Because of her strength and will to live I want to dedicate this thesis to her and all PD patients. I hope that this thesis will give people an insight in the possibilities of research on PD and maybe even a way of fighting this disease.
I would like to thank Mrs. Verduin to give me the inspiration to write this thesis and of course my supervisors.

I hope you to get more interested in PD after reading this thesis,
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Introduction: Parkinsonism and Parkinson’s disease

Parkinsonism is a term that refers to a clinical syndrome that includes many combinations of motor problems, ebradykinesia (slowness and decreased amplitude of movement), tremor-at-rest, muscle rigidity, loss of postural reflexes, flexed posture, and the freezing phenomenon). For the diagnosis of Parkinsonism not all the six features have to be present. At least two of the features need to be present, with at least one of them being tremor-at-rest or bradykinesia.
The major cause of parkinsonism is Parkinson’s disease (PD) and can be referred to as the primary parkinsonism. There are also three other types of parkinsonism [1] namely; 1) secondary parkinsonism, such as drug-induced parkinsonism and post- encephalitic Parkinsonism, 2) Parkinson-plus syndromes (presence of parkinsonism plus other neurological features), such as the diseases known as progressive supranuclear palsy and multiple system atrophy, and 3) heterodegenerative disorders in which parkinsonism is only one feature of a hereditary degenerative disorder, such as juvenile Huntington disease and Wilson disease. 
To make a good diagnosis of PD there are three helpful clues that could indicate that patients are dealing with PD rather than another category of parkinsonism[[2]; 1) an asymmetrical onset of symptoms (PD often begins on one side of the body), 2) the presence of rest tremor (rest tremor may be absent in patients with PD, it is almost always absent in Parkinson-plus syndromes), and 3) substantial clinical response to adequate levodopa therapy (usually, Parkinson-plus syndromes do not respond to levodopa therapy). In this thesis I will focus specifically on the classical PD. 

Physical and Physiological symptoms of PD
PD is a slowly progressive parkinsonian syndrome that gradually worsens in severity, and, as described above, usually affects one side of the body before spreading to involve the other side. Although the illness sometimes begins with bradykinesia, and in some patients, tremor may never develop, tremor-at-rest is often the first symptom recognized by the patient. Over time there is a steady worsening of the symptoms. If these symptoms are left untreated, this will lead to disability with severe immobility and falling. The early symptoms and signs of PD — rest tremor, bradykinesia, and rigidity — can be corrected by treatment with levodopa and dopamine (DA) agonists. When PD progresses over time, symptoms that not respond to levodopa will develop steadily, such as flexed posture, the freezing phenomenon, and loss of postural reflexes; these are often referred to as non-DA-related features of PD. 
Moreover, bradykinesia that responded to levodopa in the early stage of PD aggravates as the disease worsens and becomes no longer fully responsive to the levodopa treatment. These intractable motoric symptoms lead specific to disability with increasing immobility and balance difficulties. Although the motor symptoms of PD dominate the clinical picture, and even define the parkinsonian syndrome, many patients with PD have other complaints that have been classified as non-motor. These include fatigue, depression, anxiety, sleeping disturbance, constipation, bladder and other autonomic disturbances (sexual, gastrointestinal), sensory complaints, decreased motivation and apathy, slowness in thinking (bradyphrenia), and a declining cognition that eventually can progress to dementia. PD and the Parkinson-plus syndromes have a degeneration of substantia nigra (SN) pars compacta dopaminergic neurons in common, with a resulting deficiency of striatal DA concentration due to loss of the nigrostriatal neurons. This neuronal loss comes accompanied by an increase in glial cells in the SN and a loss of neuromelanin (NM), the pigment that is normally contained in SN dopaminergic neurons. In the surviving neurons, Lewy bodies are usually present. These bodies are intracytoplasmic, eosinophylic, inclusions. The progressive loss of the nigrostriatal dopaminergic neurons corresponds to a decrease of DA content in both the SN and the striatum. Progressive loss of the dopaminergic nigrostriatal pathway can be detected during life using PET and SPECT scans. These scans show a continuing reduction of floro-DOPA (FDOPA) and DA transporter ligand binding in the striatum and an altered secondary effect on cortical metabolism. [3-7]

DA neuron degeneration
The exact mechanism that is responsible for DA neuron degeneration in PD is still not known. Oxidative stress, excitotoxicity, depletion of endogenous antioxidants, reduced expression of trophic factors and dysfunction of protein degradation are believed to be involved in the cascade of events that will lead to DA neuron death [8-10]. Looking at several studies, there is a clear indication that neuro-inflammatory mechanisms possibly play an important role in the pathogenesis of PD, therefore, inhibition of inflammation is proposed here as a very promising therapeutic intervention [11-15]. Most cases of PD appear to be sporadic and represent interplay between both genetic and environmental influences [16]. Genetic factors may interact with early life events such as the exposure to hormones, endotoxins and neurotoxins and thereby influencing the severity and predisposition of the disease. Developmental exposure to environmental toxins (such as pesticides/herbicides), either alone and/or in co-operation with other environmental (i.e. endotoxins; hormonal dysfunctions) and/or genetic “predisposing” factors, may synergistically increase DA neuron vulnerability [16-17], these environmental factors will be discussed further in Chapter II
Treatment 
Until now, there is no cure for PD but medication or surgery can provide a relief from the symptoms. The most widely used form of treatment is L-dopa in various forms. L-dopa is transformed into dopamine in the dopaminergic neurons by L-aromatic amino acid decarboxylase. However, only 1-5% of L-DOPA enters the dopaminergic neurons and the remaining L-DOPA is often metabolized to dopamine elsewhere, causing a variety of side effects. Due to the feedback inhibition L-dopa results in a reduction in the endogenous formation of L-dopa, and eventually become counterproductive. Carbidopa and benserazide are dopa decarboxylase inhibitors. They help to prevent the metabolism of L-dopa before it reaches the dopaminergic neurons and are generally given as a combination of carbidopa and levodopa, called co-careldopa, and benserazide and levodopa, called co-beneldopa [18-20]. Duodopa is an example combination of levodopa and carbidopa, dispersed as a viscous gel. Using a patient-operated portable pump, the drug is continuously delivered via a tube directly into the upper small intestine, there it is rapidly absorbed. Another drug, Stalevo (a mix of carbidopa, levodopa and entacapone) is also available for treatment. Tolcapone is a drug that inhibits the Catechol O-methyl transferase (COMT) enzyme, thereby prolonging the effects of L-dopa, and so has been used to complement L-dopa. Due to its possible side effects such as liver failure, it is limited in its availability. A similar drug, entacapone has not been shown to cause significant alterations of liver function and maintains adequate inhibition of COMT over time. [18, 34].

Another treatment is based on dopamine agonists; the dopamine agonists bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, and lisuride are moderately effective. Each of these antagonists has its own side effects like somnolence, hallucinations and/or insomnia [19-20]. Dopamine agonists initially act by stimulating some of the dopamine receptors [21]. However, they cause the dopamine receptors to become progressively less sensitive and will eventually increase the symptoms [19-20]. Dopamine agonists can be useful for patients experiencing on-off fluctuations and dyskinesias as a result of high doses of L-dopa. Apomorphine can be administered via subcutaneous injection using a small pump which is carried by the patient. A low dose is automatically administered throughout the day and reducing the fluctuations of motor symptoms by providing a steady dose of dopaminergic stimulation [22-25]. Other drugs like selegiline and rasagiline inhibit monoamine oxidase-B (MAO-B) and reduce the symptoms. MAO-B breaks down dopamine secreted by the dopaminergic neurons will result in inhibition of the breakdown of dopamine. Metabolites of selegiline include L-amphetamine and L- methamphetamine [26]. The use of this drug might result in side effects such as insomnia. Use of L-dopa in conjunction with selegiline has increased mortality rates that have not been effectively explained [27]. Treating Parkinson's disease with surgery was once a common practice, but after the discovery of levodopa, surgery was restricted to only a few cases. Studies in the past few decades have led to great improvements in surgical techniques and surgery is currently being used in people with advanced PD for whom drug therapy is no longer sufficient [28]. Deep brain stimulation is presently the most used surgical way of treatment, but other surgical therapies that have shown promising results include surgical lesion of the subthalamic nucleus and the internal segment of the globus pallidus, a procedure known as pallidotomy [29]. Regular physical exercise and/or therapy can be beneficial to the patient for maintaining and improving mobility, flexibility, strength, gait speed, and quality of life; and speech therapy may improve voice and speech function [30-32]. One of the most widely practiced treatments for the speech disorders associated with Parkinson's disease is the Lee Silverman Voice Treatment (LSVT). LSVT focuses on increasing vocal loudness [33].





Chapter I: Prevalence and incidence of PD

Parkinson’s disease (PD) is a neurodegenerative disease with a prevalence of 100–200 cases per 100,000 persons in the general population [35]. The prevalence increases sharply with age, and most surveys show a slight male preponderance. Moreover, prevalence rates may vary depending on the geographical location and seem to be especially low in developing countries. Although there are many studies assessing prevalence, incidence studies are scarce especially in developing countries where PD patients are not recorded well and knowledge is scarce. If incidence rates are known it is maybe possible to make a connection with the place people live, the place of birth, exposure to risk factors and the enlarged risk of PD.
Based on several prevalence and incidence studies Alves and co-workers [36] made a general estimation of the incidence and prevalence rates within different age groups and different parts of the world.


I.I General Prevalence & Incidence 
Parkinsonian characteristics may be subtle at the onset of the disease, misdiagnosis is therefore not uncommon. In a community-based study, only 53 % of patients on anti-Parkinson medication, initiated by general practitioners due to suspected PD, fulfilled criteria of probable PD when investigated by neurologists [37]. Besides Parkinsonian features also often occur in patients with Alzheimer’s disease (AD) and other dementia disorders. Methodological differences between studies make direct comparison of prevalence and incidence estimates difficult. The disease is found in all ethnic groups, but with geographical differences in prevalence. Early onset of sporadic PD is rare, with about 4 % of patients developing clinical signs of the disease before an age of 50 [38] and approximately 1–2 % of the population over 65 suffering from PD. This figure increases to 3 to 5 % in people of 85 year and older [39]. As PD is mainly an illness of the elderly, it is expected to be more common in developed countries where people live longer. Most community-based prevalence studies across Europe found crude prevalence rates between 100 and 200 per 100,000 inhabitants [35]. Incidence calculations are thought to be a more precise estimate of the frequency of the disease because they are not influenced by mortality. However, there are substantial variations in reported incidence rates, most likely due to methodological differences between studies, in particular differences in case ascertainment and use of diagnostic criteria. Age-standardized incidence rates of PD in population-based studies in European countries and the USA range from 8.6 to 19.0 cases per 100,000 inhabitants per year when strict diagnostic criteria of PD are applied. As may be anticipated, door-to-door surveys and studies using broader inclusion criteria have yielded higher prevalence and incidence rate figures [40].


I.II Incidence/Prevalence in Developed Countries
In an incidence study of Leentjens and co-workers [41], the authors reported on the incidence rates of PD in The Netherlands, based on the analysis of data from an ongoing longitudinal general practice-based registration network. Their analysis was performed with data from the Registration Network Family Practices (Registratie Net Huisartspraktijken; RNH). Data was collected on all relevant current and past health problems. Before the authors could analyse the data, ‘health problems’ must be defined as ‘anything that has required, does, or may require health care management and has affected or could significantly affect a person’s physical or emotional well-being’. These problems are coded according to the International Classification of Primary Care (ICPC), using the criteria of the International Classification of Health Problems in Primary Care (ICHPPC-2) [42-43]. The register was continuously updated with information from all possible sources, including correspondence, reports and investigations from hospital-based specialists. After defining data, the age- and sex- specific incidences were calculated by using incident PD cases as the numerator and the total number of RNH participants as denominator. From 1990 to 2000 (inclusive), 139 new PD cases were identified and the overall crude incidence for the population was 22.4 per 100,000 inhabitants per year [95% confidence interval (CI): 13.1–31.7]. Analysis of the results showed an exponential increase of PD incidence with age which kept increasing on to the highest age groups. The incidence in men in this study was higher than that in women in all age groups, except in the 60- to 69-year- old. The results are shown in Table I. The authors concluded that the annual incidence of 22.4 per 100,000 per year in our population is comparable with that of two other recent European community studies, but higher than reported in most studies. The questions you can ask yourself after seeing these results are whether this incidence rate is a good reflection of the incidence of PD in the Netherlands and other developed countries, and whether the study population is representative. Another question could be whether the men and women gender really differ that much in PD incidence and whether this is the same for other countries or/and different ethnicities. According to the authors their study was accurate enough, but in an incidence study a lot of things can go wrong like incompleteness and non reliability of the registrations, differences in detection strategies etc. 

In an USA study of Eeden and co-workers [44], another PD epidemiological study amongst different ethnicity groups was performed. In this study there were some differences in PD incidence amongst difference races/ethnicity, but it is not justifiable to take the conclusion that one race is more susceptible for PD than other races or to take any other conclusions about these results. This is due to the relatively low number of cases amongst the non-white study population (see appendix 1). Surprisingly, unlike the study of Leentjens and co-workers, the overall incidence of PD amongst men was higher than in women (see appendix 1). The differences in the overall incidence between these two studies can be explained by differences in strategy, registration and accuracy. Besides, the comparisons of age- and gender-adjusted incidence rates between individual groups were none of all statistically significant. Before one could say something about differences in PD incidence rates in different ethnicity/ race groups, more studies need to be done on this topic. 


I.IV Incidence/prevalence PD Developing countries
It is suggested that less people suffer from PD in African populations [45]. In Africa, crude prevalence rates range from 7 to 43 per 100,000 [46-47] while in developed countries like the Netherlands the crude prevalence rate is about 200 per 100,000. Whether there is a true difference in susceptibility of the African population would be of great epidemiological importance, in terms of investigating the cause(s) of PD. However, these differences in prevalence rates could be due to several factors: under-diagnosis of PD in these communities, differences in case finding methods, differences in diagnostic criteria used and early mortality owing to other causes in these populations. Previous studies in sub-Saharan Africa (SSA) have been performed using different methods, making them difficult to compare with each other and other studies elsewhere in the world: door-to-door studies carried out by Osuntokun et al. [48] (Nigeria); case finding from neurological clinics and neurological admissions by Harries et al. [49] (Kenya) and Bower et al. [50] (Ethiopia); retrospective review of hospital admissions by Lombard and Gelfand [45] (Zimbabwe); and data on the use of levodopa (L-dopa) usage by Cosnett et al. [51] (South Africa). As there are few studies, papers describing both idiopathic PD and Parkinsonism are included. 

I.IV.I Door- to- Door Study
In 1986 a door-to-door study was performed by Osuntokun et al. [48] in a Nigerian town. The authors looked at all neurological disorders, not specifically PD. They used a two-step procedure, with a screening questionnaire that was carried out by non-medically trained administrators, followed by an expert history and examination if they answered positively to the questionnaire. Nearly 95% of the population took part in the study. Only 11% of the population were over 50 years (compared with over 33% in the United Kingdom). No diagnostic criteria for PD are described. Their results showed a point prevalence rate for PD of 10 per 100,000, only two cases were identified. The sex and gender of the cases were unknown. A second door-to-door survey was carried out by Tekle- Haimanot in rural Ethiopia between 1986 and 1988. Again, this study, which included a population of 60,820, looked at all neurological disorders, and not just PD. Participation rates were between 95 and 100%. The median age of this population was 14.5 years with 59% of the population being <20 years old. They found four cases of PD (all male), giving a crude prevalence rate of 7 per 100,000. No diagnostic criteria for PD were documented. The authors state that the reason for the difference in the prevalence of PD among white populations is due to the difference in population age structure. However the data was not standardised for age. [48] This study makes it clear that accuracy is required to perform a reliable epidemiological study.

I.IV.II PD management in Africa




As PD is mainly an illness of the elderly, it is expected to be more common in developed countries where people live longer.
	Most community-based prevalence studies across Europe found crude prevalence rates between 100 and 200 per 100,000 inhabitants.
	Age-standardized incidence rates of PD in population-based studies in European countries and the USA range from 8.6 to 19.0 per 100,000 inhabitants when strict diagnostic criteria of PD are applied. 
	In the study of Leentjens et al. [41] The overall crude incidence for the population was 22.4 per 100,000 per year
	In the study of Leentjens et al. [41] as well as in the study of van den Eeden et al. [44] the incidence rate of PD for man was higher as in women.

On the African continent it is still unclear how many people suffer from PD so there is still no clear incidence or prevalence rate reported. Parkinson’s disease is present in SSA and even those who are diagnosed and can afford treatment still have a difficult clinical course:
	Medical treatment is difficult to find, rarely available or affordable.
	No major improvements have been made in the past 20 years.
	Most people with PD remain undiagnosed and untreated in the community.
	Patient education and information are severely lacking 
	Generally, no written information or long-term follow-up is available.
	Only flying services are available for patients with PD in the developing world in comparison with those available and taken for granted in the developed world [52]. 








Chapter II: Risk factors in PD

II.I The inheritance of PD
The most cases of primary Parkinsonism are sporadic, but in 10% of cases a positive family history is seen. A genetic base for PD had long been controversial. Twin studies have indicated a greater role of genetic factors in younger onset patients than in patients with onset over the age of 50s [53].
In the last few years several gene mutations have been discovered, by painstaking linkage and genome analysis, to cause PD in a small number of families. Ten monogenic forms of PD, labelled PARK 1-10, have been identified with genes identified in five. They are present either as autosomal dominants or autosomal recessive mutations. Identification of these mutations has led to the recognition that the ubiquitin–proteasome system is an important pathway that may be disrupted in PD [54-55]. Studies are ongoing to identify additional genes that may contribute to PD susceptibility, particularly in late-onset families without a clear pattern of disease inheritance. More investigation about the inheritance of PD is required. Other genes that probably are candidates in PD are genes that are involved in determining dopamine signalling and disposition. Polymorphisms in the genes encoding monoamine oxidase-B (MAO-B) and monoamine oxidase A (MAO-A) have been explored as potential risk factors for PD (see Chapter IV). 

II.II Environmental Factors
The event that suggested that environmental factors might contribute to the etiology of PD was the recognition of a clearly induced state of acute parkinsonism by accidental poisoning from MPTP (1- methyl-4-phenyl-1, 2,5,6-tetrahydropyridine), an impurity that was a by-product in batches of illicitly produced “synthetic heroin” MPPP (1-methyl-4-phenyl-4-propionoxypiperidine; also known as PPMP in Davis et al. [56]).
Although the absence of an additional methyl group on the 4-phenyl-piperidine ring, MPPP is identical to the narcotic alphaprodine (1,3-dimethyl-4-phenyl-4-propionoxypiperidine; also known as Nisentil), which is 26-fold more potent in rats than its better-known isomer, Demerol (meperidine; pethidine; 1-methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester). In addition to MPTP toxicity, there are also several reports suggesting roles of other compounds in the induction of parkinsonism; the best documented is manganese [57-59]. Manganese toxicity also produces dystonia and was observed in manganese miners and ore-crushing workers. But the toxicity from MPTP is much more specific than that from manganese by affecting selectively the DA neurons. Namely, manganese affects other basal ganglia neurons as well. Although these and other chemical poisons, like carbon monoxide, can induce parkinsonism, this is classified as secondary- and not primary-parkinsonism or PD. In addition, rural living and pesticide and herbicide exposure at early life have also been suggested from epidemiological studies to play a major role in inducing PD [60]. A good example of a prospective study on the risk of pesticides is the cohort study of Japanese men in Hawaii, originally established for the investigation of risk factors: 7,986 Japanese–American men born between 1900 and 1919 were enrolled in the longitudinal Honolulu Heart Program, with a median length of follow-up of 27 years. The relative risk of PD was 1.9 (95% CI, 1.0–3.5) for men who had worked more than 20 years on a plantation compared with men who never worked in a plantation (sugarcane and/or pineapple). The age-adjusted incidence of PD was higher in men exposed to pesticides than in men who never did plantation work [80].

II.III Environmental Risk Factors During Early Life
Neuropathological studies and animal models show that exposure to environmental neurotoxicants can determine progressive damage in the substantia nigra many years before the onset of clinical parkinsonism. Therefore, PD, like other neurologic diseases related to aging, may be determined by exposures from the environment early in life or even during pregnancy.

II.III.I Infections in Early Life
Inflammation has been proposed as one of the possible pathogenic mechanisms for PD [61]. The pro- inflammatory cytokine tumour necrosis factor α(TNF- α) kills DA neurons in vitro and is elevated in the brains of patients with PD [62]. Intrauterine infection might lead to nigral cell loss in the fetal brain and a subsequent decrease in DA neurons in the substantia nigra secondary to inflammation. Bacterial vaginosis during pregnancy is characterized by the presence of lipopolysaccharide (LPS), a bacteriotoxin that is an inducer of TNF-α [63]. These compounds are increased in the chorioamniotic environment of infected women and could interfere with the normal development of DA neurons in the fetus.
The results of Ling et al. [64] showed the possibility that, after intrauterine infection, some newborn children had limited striatal neurochemical reserves and a reduced DA cell count. This reduced reserve might enlarge the risk of developing PD in adults. Most epidemiologic studies on infection during early life and risk for PD were conducted in England. A population-based study was conducted in 42 general practices in eastern Hertfordshire [65]. PD cases were subjects born after 1910 and diagnosed by a neurologist or a geriatrician, and controls were subjects in the same general practices matched by age and sex (172 cases, 343 controls). Records in the first part of the 20th century were used to obtain information about birth weight and growth during the first year of life. The subjects answered a questionnaire about sibling ship, position in the birth order, type of housing, other features of the environment in early life, and experience of the common infections of childhood. Subjects were more likely to have suffered croup (odds ratio (OR) = 4.1; 95% confidence interval (CI), 1.1–16.1) or diphtheria (OR = 2.3; 95% CI, 1.1–3.6) these infection probably enlarged their risk of developing PD. The results of this study do not suggest that poor growth in fetal life or infancy is important in the etiology of PD but do suggest that early infection might have a role in susceptibility to PD. Some investigators have examined the relationship between influenza pandemics and PD, testing the hypothesis that PD could follow intrauterine influenza [66]. Three groups of PD patients were identified through specialty clinics or general practitioners. Matched controls were selected which were born in the same 5-year period as the index patient. For each group and each calendar year, the parkinsonian ratio to control births was calculated. This risk ratio was used to estimate the relative risk of each cohort developing PD in later life. Subjects born in 1892, 1904, 1909, 1918, 1919, and 1929 (years encompassing the influenza pandemics of 1890–1930) appeared to have an increased risk of developing idiopathic PD compared with subjects born in other periods, and four of these years coincide with years of influenza pandemic. The PD vs. control birth ratio showed a significant correlation with the crude influenza mortality for the year of birth during the period from 1900 to 1930 [66]. People born around 1900 had a risk of PD 5 times that of people born around 1930 [67]. The strong variation of PD risk from year to year of birth shown in some of the previous studies would be consistent with the action during development of an infectious agent, more likely a virus that typically occurs in epidemics. These studies were all based on the hypothesis that intrauterine influenza infection or other viral insults may be cytotoxic to the developing fetal substantia nigra and could enhance the risk of PD after a latent period [68-69]. Data on the season of birth are not very good arguments for a relationship between influenza and PD because there are other potential factors that are characterized by a seasonal variation that could be responsible for the observed association. Epidemiologic studies on the relationship between infections early in life and PD are inconclusive and again more research is required.

II.III.II Place of Birth
The place of birth can be used as a surrogate for early- life exposure. And so the state of birth in the United States was studied as an exposure of interest for PD [70]. The outcome was measured by death, using the death certificates from U.S. death information in 1981. The measure of effect was the proportionate mortality ratio (PMR), using all the other deaths in the United States as the comparison group. Potential confounders such as age, gender, and whether the state of birth was the same as the state of death were included in a logistic model. Cerebrovascular disease deaths were used as a negative control group because there is no association with childhood exposure; multiple sclerosis was used as a positive control because it has been found related to geography in childhood. The results showed a very high PMR for Utah (45/10,000), Idaho (37/10,000), Colorado (31/10,000), New Mexico (32/10,000), Kansas (32/10,000), and Nebraska (33/10,000), with a west to east gradient. The lowest PMR was registered in Delaware (7/10,0000). However, it is important to mention that PMR can be affected by the distribution of other causes of death. The PMR rates from west to east can possibly be explained by the fact that many pesticide (especially Dieldrin and Lindane) and herbicide manufacturing facilities were settled in these area’s until 1999. Like mentioned earlier, pesticide and herbicide exposure can have a PD inducing effect. In contrast, an study conducted by Kurtzke and Goldberg (1988) [71] using death certificates showed that age-adjusted death rates of PD presented a north–south gradient, similar to that found for multiple sclerosis. Only the state where the PD subject was resident at the time of death was considered in the analysis. Geographic studies based on death certificates may be affected by the underestimation of PD cases that can be inhomogeneous across different geographic areas. Studies of geographic variation need to be interpreted with caution because many factors beyond environmental exposure could determine the geographic patter n of a disease. Chance, migration, differences in procedures used to diagnose/classify cases, and access to medical care are other possible alternative explanations [72].


II.III.III Toxic Exposure Early in Life
Clinical parkinsonism can be caused by a series of previous mentioned exogenous factors such as viruses, poisoning with toxic substances such as MPTP and manganese, and trauma. These clinical observations suggest that environmental risk factors are important for the etiology of PD. Several environmental toxicants related to the occupation in agriculture have been implicated as risk factors in PD.
The chemical structure of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of MPTP, is very similar to the herbicide paraquat (PQ) [73]. Animal experiments have clearly shown the selective action of PQ on the DA system. Systemic PQ given to mice through repeated intraperitoneal injections induces selective damage of DA neurons in the pars compacta of the substantia nigra [74]. The cell loss in this model was dependent on dose and age. The presence of a different effect of the exposure at different ages in this model showed a possible interaction of toxic environmental exposures with normal aging [74]. Chronic, continuous, and systemic exposure to rotenone, commonly used as an insecticide in gardening, selectively inhibits mitochondrial complex I, causing selective degeneration of the nigrostriatal system with accumulation of cytoplasmic inclusions containing ubiquitin and α-synuclein [75]. In mice, PQ exposure determines an up-regulation of α synuclein, accelerating the formation of aggregates in the substantia nigra [76]. This confirms previous observations in vitro that postulated a selective binding of PQ with partially folded α-synuclein [77]. Toxic exposures that occur early in the development could determine long-term pathology in the central nervous system. A model exploring this hypothesis should explore the possibility that early damage to the DA system could result in cell loss or high vulnerability to a second environmental risk factor associated with PD (two-hit model). A similar kind of model was hypothesized for combined exposure to PQ and the fungicide maneb (MB) during development. The combined action could permanently change the nigrostriatal DA system and enhance its vulnerability to subsequent neurotoxicant challenges. Mice exposed to two neurotoxicants, PQ and MB, and subsequently exposed again as adults presented with the most severe damage. They showed a 70% reduction in motor activity, 2 weeks after the last toxic dose [78]. Developmental exposure to PQ or MB alone produced minimal changes, whereas a significant decrease in nigral cell counts was observed after adult exposure. Striatal DA levels were reduced with 37% after only the developmental exposure to PQ plus MB, but after a second exposure during adulthood, striatal DA levels were reduced with 62%. This experiment suggests that the exposure during development to the two toxicants produced a state of masked toxicity that was revealed after adult re-exposure. So exposure to specific pesticides during the prenatal period can produce a limited but selective amount of lesions in the nigrostriatal system. These developmental lesions might determine an enhanced susceptibility that, in combination with later exposure to other toxicants (e.g., PQ), may be involved in the induction of PD during aging.




As a conclusion, several research data suggest that the use of pesticides or surrogates of pesticide exposure increase the risk of PD. However, there are still too few epidemiologic studies specifically addressing the issue of toxic exposure early in life. While the search continues for environmental factors that can be associated with PD, several studies have shown that cigarette smoking, coffee drinking and estrogen levels are inversely associated with PD.

Chapter III: Neuronal cell death

As described in the introduction, the currently available therapies like levopoda therapy for PD are symptomatic and become less effective over time due to progression of the underlying disease process. Due to this progressive nature of PD and the fact that neuronal degeneration in the SN is slow, therapeutic intervention of PD is especially aimed at blocking or slowing down the degenerative process. Neuroimaging and autopsy data indicate that there is a preclinical period of 4-5 years before the PD symptoms appear. The rate of cell loss and dopaminergic function in the striatum is most likely to be in the order of 10% per year in PD patients. Both PET and SPECT imaging are able to detect a decline in striatal dopamine function before clinical symptoms appear which may make it possible to begin neuroprotective intervention during the preclinical phase [3-7]. The neurodegenerative process in PD is likely to involve a cascade of inter-related events; oxidative stress, mitochondrial dysfunction, excitotoxicity with excess formation of NO and O2 radicals, and inflammatory changes, leading to both apoptotic and necrotic cell death (Figure 1) [8-10]. These events offer potential targets for neuroprotective therapeutic strategies [11-15]. Because the dopaminergic neurons are dysfunctional for some time before they are irreversibly damaged, both neurotrophic and anti-apoptotic agents may be used to prevent delayed cell death and/or restore function [34].









III.I Mechanisms of cell death in the SN
Even in the general population there is a gradual decline in neurons of the SN pars compacta and dopamine content of the basal ganglia with age. In idiopathic PD the symptoms appear when about 70 to 80% of the striatal dopamine [81] and about 50% of the nigral dopamine neurons are lost [82-83]. PD might progress in two ways. There might be an accelerated rate of cell death so the critical level of dopamine loss is reached during the normal life-span. Alternatively an acute insult or stress may cause rapid but partial loss of substantia nigra neurons. This acute insult is inspired by the earlier mentioned MPTP toxicity and the environmental toxin theory [84].








Figure 2: Rate of progression in Parkinson’s disease. Model of disease progression. Normal age- dependent cell loss in the substantia nigra is shown in blue. PD symptoms become apparent after a critical level of cell loss, the ‘symptom threshold’. In the ‘accelerated ageing’ model of PD (red), cell loss starts early and progresses more rapidly, whereas in the ‘double hit’ or ‘assault’ model (brown) there is subthreshold cell loss resulting from acute toxic insult, followed by a normal rate of age-dependent cell loss until the critical threshold is reached. Recent evidence favours an even more rapid exponential cell loss, departing from normal numbers only a few years before symptom onset (green) [34].

III.II Mechanisms involved in neuronal cell death

III.II.I Oxidative stress and mitochondrial dysfunction
Oxidative stress is a result of overabundance of reactive free radicals secondary to either an overproduction or a failure of cell buffering mechanisms that normally limit their accumulation. Excess reactive species can react with cellular macromolecules and thereby disrupt their normal functions. Oxidative damage to proteins, lipids, and nucleic acids has been found in the SN of patients with PD [87-89]. Both overproduction of reactive oxygen species (ROS) and failure of cellular protective mechanisms appear to be operative in PD. Dopamine metabolism promotes oxidative stress through the production of quinones, peroxides, and other ROS [90-91]. Mitochondrial dysfunction is another source for the production of ROS, which can then further damage mitochondria. Complex I activity is diminished in the SN of PD patients [92], while inhibitors of complex I, such as MPP+ and pesticides like rotenone, can cause a Parkinsonian syndrome in animal models [93-95]. The mechanisms responsible for mitochondrial dysfunction in PD are not well understood, but inherited or acquired mutations in mitochondrial DNA may be one of the causes [89-98]. Increased iron levels seen in the SN of PD patients also promote free radical damage, particularly in the presence of neuromelanin. Other evidence is the impairment of endogenous protective mechanisms in PD. The antioxidant protein glutathione is reduced in post-mortem PD nigra [99-101]. Several of the genes linked to familial forms of PD appear to be involved in the failure of protection against oxidative stress, including PTEN-induced putative kinase (PINK1) and DJ-1 [102-105]. There are different strategies that have been proposed to limit oxidative stress in PD. These strategies include inhibitors of monoamine oxidase, a key enzyme involved in dopamine catabolism; enhancers of mitochondrial electron transport, such as Coenzyme Q10; compounds that can directly extinguish free radicals, such as vitamin E; and molecules that can promote endogenous mechanisms to buffer free radicals, such as selenium. The many kinds of agents have the advantage of being tolerated with only a few adverse effects, but there is still no clinical proof of effectiveness [106].

III.II.II Protein aggregation and misfolding
Protein aggregation and misfolding are important mechanisms in many neurodegenerative disorders, including PD, Alzheimer's disease, and Huntington's disease. While the proteins involved in these disorders are different, each is associated with characteristic aggregates of misfolded protein, and these abnormal aggregates appear to have some toxic properties. In PD, the primary aggregating protein is alpha-synuclein (α-syn), whose link to PD was first identified through rare families with autosomal dominant PD caused by mutations in this protein [107-110]. Although mutations in α-syn are found in a very small number of inherited PD cases, α-syn is the major component of Lewy bodies and Lewy neurites found in sporadic PD [111]. Gene duplication of the α- syn locus also causes PD, further supporting the central role of this protein in PD pathogenesis [112]. Point mutations [113], over expression [114], and oxidative damage of α-syn [115] all promote self-aggregation. While some studies link α-syn to PD, the mechanism by which overabundance or aggregation of α-syn cause neuronal injury is not understood yet. It is still unclear which molecular form of α-syn is toxic. Hypotheses include toxic effects of oligomers on cell membranes or proteosomal function, effects of α-syn on gene transcription or regulation, interactions of α-syn with cell signalling and cell death cascades, alterations in dopamine storage and release, and α-syn-mediated activation of inflammatory mechanisms [116-119].
Recent studies implicating parkin and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in genetic forms of PD reinforce the connection between protein aggregation and PD pathogenesis [120-121]. Parkin is an E3 ubiquitin ligase involved in targeting misfolded proteins for degradation, mutations of this gene found in genetic forms of PD disrupt its E3 ubiquitin ligase activity. Surprisingly native α-syn does not appear to be a substrate for parkin [122], and brains from patients with parkin-associated PD do not usually contain Lewy bodies [123]. Parkin does appear to have a variety of other substrates that may play a role in protein turnover and degradation, including HSP70, which is known to modulate α-syn toxicity [124]. UCH-L1 serves as an ubiquitin recycling enzyme in neurons, and its dysfunction promotes aggregation of damaged proteins, including α-syn [125]. So overproduction or impaired clearance of α-syn, resulting in aggregation, may be an important mechanism for PD. With this information new potential neuroprotective therapies could be developed like inhibitors of α-syn aggregation. Molecules that promote protein clearance could also have therapeutic potential in genetic PD patients. Promoters of protein clearance could include enhancers of parkin or UCH-L1 function, or molecules that promote proteosomal or lysosomal degradation pathways [126]. So still, more research is required.

III.II.III. Neuroinflammation
In PD pathogenesis, neuroinflammation has been recognized as an important mechanism of the disease [127-128]. Activation of microglia has been demonstrated in SN and striatum from post-mortem PD brains and in PD animal models [129-131]. Pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, are elevated in the CSF and basal ganglia in PD patients [132]. The SNpc of PD patients shows large numbers of activated microglia and reactive astrocytes. These two cell types are presumably responsible for the increase of these cytokines in the nigro-striatal pathway since they are able to produce and release cytokines. In turn, these cytokines may also activate the surrounding microglia and astrocytes but may also act on neurons [61, 129]. In vitro, both aggregated and nitrated forms of α-syn can directly trigger a microglial response and release of cytotoxic factors [133-135]. In mouse models, α- syn or modified forms of the protein can trigger both microglial and humeral responses [136-137] and inhibition of NF-KB signalling seems to be neuroprotective [138]. Given the evidence for neuroinflammation in PD, agents with anti-inflammatory effects have been investigated for their neuroprotective potential. Many of these anti-inflammatory drugs are already in common use for other purposes of neuroprotection. Non-steroidal anti-inflammatory agents (NSAIDs) for example, reduce dopaminergic cell death in animal and culture PD models [139-141], and minocycline, another agent with anti-inflammatory capabilities, is currently being investigated in human trials [142]. More investigation about this topic is needed also because it is still not clear whether the inflammatory response is a cause or a consequence of dopaminergic cell loss, and it is not known the release of inflammatory factors is a part of a harmful or protective mechanism toward the dopaminergic neurons.

III.II.IV Excitotoxicity
Excitotoxicity has been implicated as a pathogenic mechanism in several neurodegenerative disorders including PD. IN the mammalian central nervous system glutamate is the primary excitatory transmitter and primary driver of the excitotoxic process. Dopaminergic neurons in the SN have high levels of glutamate receptors and receive glutaminergic innervation from the subthalamic nucleus and cortex. Excessive NMDA receptor activation by glutamate increases intracellular calcium levels that activate cell death pathways [143]. Calcium influx produced by excessive glutamate receptor activation can also promote peroxynitrite production through the activation of nitric oxide synthase [144]. Levels of 3-nitrotyrosine, a marker of peroxynitrite formation, are increased in post-mortem SN from PD patients. NMDA receptor antagonists protect against dopaminergic cell loss in MPTP models [145-146], but there is a major limitation to clinical application because of the low potency and poor tolerability of the currently available agents. For example, riluzole has glutamate antagonist properties, but  failed to show any neuroprotective effect in a small clinical trial [147]. Neuroprotective effects have also been attributed to amantadine, which has modest NMDA antagonist properties as well as other actions [148]. Human dopaminergic neurons have NMDA receptors with an unusual subunit composition characterized by abundant expression of the NR2D subunits, which have physiological and pharmacological properties distinct from the receptor types found in many other regions of the brain [149]. The development of NMDA antagonists with selectivity of specific channel subunits can be a potential neuroprotective strategy 

III.II.V Apoptosis
Apoptosis (programmed cell death) is a mechanism that has been demonstrated to participate in neural development and play an important role in some forms of neural injury. There are still some questions about whether apoptosis is directly involved in PD. Several pathological studies have revealed signs of both apoptotic and autophagic cell death in the SN of PD brains [150-152], although the extent is limited. This is perhaps because of the slow process of cell death in PD. A Recent in vitro study of Sun et al. (2010) [153] indicate that Insulin like growth factor-1 (IGF-1), a neurotrophic factor, protects PC12 cells exposed to MPP+ from apoptosis via the GSK-3beta signalling pathway, this neurotrophic factor is absent in PD. Alterations in cell death pathways are unlikely to be the primary cause for PD, but both apoptotic and autophagic cell death pathways are possibly linked to oxidative stress, protein aggregation, excitotoxicity, or inflammatory processes [154]. It is possible that alterations in cell death pathways might trigger some of these pathological processes. The activation of the cell death pathways most likely represents end-stage processes in PD neurodegeneration. Therefore, inhibitors of these cell death pathways have been proposed as potential neuroprotective agents regardless of the initial cause for neurodegeneration in PD (see also Chapter IV). 

III.II.VI Loss of neurotrophic factors
The loss of neurotrophic factors has been implicated as a contributor to cell death observed in PD. The neurotrophic factors brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), and nerve growth factor (NGF) have all been demonstrated to be reduced in the nigra in PD [155-157]. Treatment with growth factors has therefore been proposed as a potential neuroprotective therapy in PD. Indeed, the potent ability of these agents to stimulate growth and branching of dopaminergic neurons suggests that they may be useful neuroprotective treatments, even if deficiency of the factors is not the primary cause of the disease process. 
However, issues relating to compound delivery and potential side effects have limited the clinical application of this treatment strategy. The recent identification of conserved dopamine neurotrophic factor (CDNF) and mesencephalic-astrocyte–derived neurotrophic factor (MANF), which constitute a new class of neurotrophic factors active against dopaminergic neurons, may provide new hope for therapeutic approaches to neurodegenerative disorders based on neurotrophic factors or downstream components of their signalling pathways [158-159]. Glial cell-line derived neurotrophic factors (GDNF) and CDNF can protect and repair the nigrostriatal dopaminergic system in animal models of PD in vivo. Despite promising clinical data, intracerebroventricular infusion of GDNF in PD patients resulted in no therapeutic benefit and produced serious side effects [160]. The poor outcome in the clinical trials with GDNF may result from the insufficient concentration at the site of neurodegeneration. GDNF binds with high affinity to heparin sulphates in the extracellular matrix (ECM) that limits the volume of its distribution. It is therefore important to find another or other neurotrophic factor(s) with a low affinity to ECM [161-162]. CDNF and MANF are secreted proteins with eight cysteine residues. MANF showed protection of embryonic nigral dopaminergic neurons in vitro [159,163]. MANF protein is up regulated in cerebral ischemia in rats and is cytoprotective against endoplasmatic reticulum (ER) stress in various cell lines [159,164]. CDNF and MANF are both expressed in the striatum. MANF and CDNF provide better protection against DA degeneration than GDNF because their local diffusion and transport profiles are more efficient. Protection of striatal dopaminergic cells may be achieved with various neurotrophic factors acting on different neuronal circuits [165]. Although in vitro studies on CDNF and MANF look promising for the protection against PD; it’s still not clear what the effects of these compounds are in vivo. This extrapolation requires more caution.

Chapter: V Neuroprotective factors





V.I Adenosine receptor antagonists
Several epidemiological studies have indicated that caffeine may have some influence on the incidence of PD, at least in men [167-168]. The finding that caffeine mediates its action by antagonizing adenosine receptors led to the evaluation of adenosine receptor antagonists as potential neuroprotective factors. In the striatum, the A2a receptor can heterodimerize with the D2 receptor to inhibit dopamine signalling [169-170], while inhibition of the A2a receptor can promote dopamine function. Two small clinical trials of the A2a antagonist istradefylline has demonstrated potential symptomatic effects in advanced PD [171-172]. Recent research has even suggested that A2a antagonist also be neuroprotective. Both caffeine and istradefylline are neuroprotective in the MPTP model [173-174]. A potential advantage of these antagonists is that they have also been shown to be neuroprotective in non-dopaminergic brain areas in animal models so that they also protect against PD neurodegeneration found in regions besides the SN. In Chapter IV the neuroprotective role of caffeine will be discussed more specifically.

VI.II Anti-inflammatory agents
As mentioned in Chapter III, inflammation has been recognised as one of the possible pathological mechanisms for PD [67]. Anti-inflammatory agents, like Nonsteroidal anti-inflammatory drugs (NSAIDs) and minocycline have been pursued to be potential disease-modifying treatments against PD [175-176]. In vivo and In vitro studies both have shown that certain NSAIDs, like aspirin, have neuroprotective qualities. The only problem is that it is not yet known at what dose or exposure time these agents will provide neuroprotection [177]. Different epidemiological studies have shown different and conflicting results. In a study of Chen et al. the results showed that NSAID use can lower the risk of PD by 45% while a follow-up study of the same group of researchers have shown that only ibuprofen has this effect [178]. Also other studies did not show any significant neuroprotective effect of NSAIDs [179-181]. So it is still unclear that any of the currently available NSAIDS have neuroprotective properties in PD. Still, targeting of neuroinflammation mechanisms can be a solution to prevent, cure or even slow the disease process of PD. An alternative approach of targeting neuroinflammation may be the use of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) These statins are a class of drug used to lower cholesterol levels. These drugs have also anti-inflammatory effects, including reduction of nitric oxide and superoxide production by microglia [182]. They also may play a role in scavenging free radicals [183]. The use of statins, especially simvastatin, has been shown to reduce dopamine loss in acute MPTP animal models and is associated with reduced PD incidence [182]. Minocycline is a second generation tetracycline that has been used as antimicrobial agent. This agent showed anti-inflammatory effects that were independent of its microbial activity. Minocycline can block microglial activation and therefore may also have anti-apoptotic activity. In both MPTP and 6-OHDA animal models the agent protects against dopaminergic cell loss [184-186]. 

IV. III Alpha-synuclein-directed therapies
Alpha-synuclein appears to be an important mediator of toxicity in PD. Disruption of α-syn aggregation has been the focus of research to develop new therapies against PD. This aggregation can be reduced by several ways: 1) by reducing the α-syn protein; 2) by increasing the clearance of α-syn; 3) by preventing and reducing chemical modifications that can promote aggregated species; and 4) by the direct interference with aggregation. Methods to reduce α-syn protein production include small-molecule modifiers of transcription and RNAi-based methods, knocking down translation.[187] Increasing the α-syn clearance can be done by activating proteosomal or lysosomal pathways. Another option is to promote chaperon function or activation of lysosomal degradation.[188-189] As oxidative modification and phosphorylation of α- syn both promote aggregation of α- syn, antioxidant therapies and kinase inhibitors could also help reduce α- syn aggregation and toxicity [190-191]. The direct blockage of α- syn could be developed into therapeutic strategies for PD. Peptide- based inhibitors have been developed that can block α-syn self association and aggregation [192-193]. Although promising, these therapies are still in an early stage and need more research.


IV. IV Kinase inhibitors
Mutation in the Leucine-rich repeat kinase 2 (LRRK2) gene is the most abundant genetic cause of PD [194-195]. The gene itself codes for a large protein called dardarin. This protein contains a serine/threonine kinase domain and a GTPase domain. The exact function of this protein is not known jet, but an increase in kinase activity is associated with the most common pathogenic mutation of the gene [196]. The evidence that pathogenic mutations increase this activity makes it an important target for neuroprotection therapy. Kinases are good targets for small molecule therapies and certain therapies for other disease are often based on inhibition of kinase activity. Still, the development of LRRK2 kinase inhibitors is very difficult because the endogenous substrates for LRRK2 are unknown. The function of the gene and its protein needs to be further characterised before the kinase inhibitor can be used in neuroprotective therapy.

IV. V Trophic factors
These factors are being used in neuroprotective therapies against PD for a long time and still have a promising potential for future research. The factors themselves are very well known, no further detail about the cell death mechanism in PD is needed for a trophic factor approach. Trophic factors enhance dopaminergic survival, independent from the mechanism of cell death. But on the other hand, they directly target the dopaminergic deficit and not the non-dopaminergic aspects of the disease. A good example of a well known neurotrophic factor is Insulin-like growth factor 1 (IGF-1), which has been shown to prevent neurodegeneration and promote regeneration in many animal models of PD. For example, administration of IGF-1 or the N-terminal fragment of IGF-1 given shortly after a 6-OHDA lesion prevented the loss of dopamine neurons in the SN and reversed behavioural abnormalities [197]Guan et al., 2000 (​http:​/​​/​www.sciencedirect.com.proxy.library.uu.nl​/​science?_ob=ArticleURL&_udi=B6WFG-4PTMXYM-1&_user=3021449&_coverDate=01%2F31%2F2008&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000021878&_version=1&_urlVersion=0&_userid=3021449&md5=391274547bd629d52a77d3338984a12c" \l "bbib22​) J. Guan, R. Krishnamurthi, H.J. Waldvogel, R.L. Faull, R. Clark and P. Gluckman, N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats, Brain Res. 859 (2000), pp. 286–292. Article (​http:​/​​/​www.sciencedirect.com.proxy.library.uu.nl​/​science?_ob=ArticleURL&_udi=B6SYR-3YSXRPP-G&_user=3021449&_coverDate=03%2F24%2F2000&_fmt=full&_orig=search&_cdi=4841&view=c&_acct=C000021878&_version=1&_urlVersion=0&_userid=3021449&md5=c91968d536f507eb088bd9ea4278fd30&ref=full​) | PDF (778 K) | View Record in Scopus (​http:​/​​/​www.sciencedirect.com.proxy.library.uu.nl​/​science?_ob=RedirectURL&_method=outwardLink&_partnerName=655&_originPage=article&_zone=art_page&_targetURL=http%3A%2F%2Fwww.scopus.com%2Finward%2Frecord.url%3Feid%3D2-s2.0-0034708539%26partnerID%3D10%26rel%3DR3.0.0%26md5%3D2b55a4db659676a6298991bbb03aa186&_acct=C000021878&_version=1&_userid=3021449&md5=7a361ba10aaa3177c65a891f68babdfb" \t "outwardLink​) | Cited By in Scopus (35) (​http:​/​​/​www.sciencedirect.com.proxy.library.uu.nl​/​science?_ob=RedirectURL&_method=outwardLink&_partnerName=656&_originPage=article&_zone=art_page&_targetURL=http%3A%2F%2Fwww.scopus.com%2Finward%2Fcitedby.url%3Feid%3D2-s2.0-0034708539%26partnerID%3D10%26rel%3DR3.0.0%26md5%3D2b55a4db659676a6298991bbb03aa186&_acct=C000021878&_version=1&_userid=3021449&md5=986341c57e7a209ebbe982cc3dfbd9c5" \t "outwardLink​). 




Epidemiological studies have shown that uric acid might be a potential neuroprotective agent in PD. Uric acid is an antioxidant that acts by scavenging reactive oxygen and nitrogen species [199]. Several studies have shown that subjects with high serum urate levels have a decreased incidence of PD [200-201]. In the early stage of PD the higher plasma urate levels correlates with slower disease progression [202]. In culture (in vitro), uric acid can reduce the dopaminergic cell death in response to rotenone (insecticide) and homocysteine [203]. Recent studies have shown that a urate-rich diet could help to reducing the risk of developing PD and even could serve as a neuroprotective therapy in PD [204]. The problem with urate-rich diets is that it causes a higher risk of developing gout and cardiovascular diseases. Another surprising and promising neuroprotective compound, which also can act as antioxidant, is nicotine, and will be discussed in the next chapter.

Chapter: V Three important neuroprotective factors










Animal model	Nigrostriatal insult	Nigrostriatal treatment regimen	Protection	References
Rats	6-OHDA	Injection, drinking water	Improvement in behavioural deficits and molecular/functional measures in striatum	[114,115, 120, 121]
Monkeys	MPTP	Drinking water	Improvement in molecular and functional measuresin striatum	[101, 124, 125]


















Although smoking is not rational and hazardous, these data are useful and may provide insight about mechanisms to reduce the occurrence of PD. Besides, it can provide a new treatment strategy to manage PD.
Many studies on the influence of smoking on the protection against nigrostriatal damage have been performed. Experiments with different parkinsonian animal models have provided the evidence that nicotine exposure improves dopaminergic markers and function in the lesioned striatum, the brain region that is predominantly affected in PD [215-218] (Also see Table IV). These data will provide a base for the suggestion that nicotine in smoke may contribute to the neuroprotective effect of tobacco use in PD.

V.I.II Nicotine neuroprotective but not neurorestorative
Although experiments in animal models have proven that nicotine may have neuroprotective effects on nigrostriatal damage and probably on the protection for PD, the question is raised whether nicotine only protects against developing damage and/or whether it can also restore integrity of damaged dopaminergic neurons. In a very recent study of Quik et al. [219] the authors tested whether nicotine given before and/or after nigrostriatal damage improved striatal dopaminergic function in two well-established parkinsonian animal models, unilateral-lesioned 6-hydroxydopamine (6-OHDA) rats and MPTP-treated monkeys. This test was done to distinguish the two alternatives; neuroprotective and neurorestorative. In the rat study, animals were given nicotine both before and after an unilateral 6-OHDA-induced lesion of the medial forebrain bundle and the data were compared to data on rats exposed to nicotine given two weeks after lesioning only. The results showed that combined nicotine pre- and post-treatment reduced behavioural deficits and ameliorated lesion-induced losses of striatal dopaminergic markers. But nicotine administered two weeks after lesioning did not have these same effects. In a monkey study, there was a similar effect; here the result was improvement in striatal dopaminergic markers when nicotine was given before and during the development of nigrostriatal damage. However, nicotine treatment did not improve dopaminergic integrity in the striatum of monkeys with pre-existing nigrostriatal damage. These data showed that nicotine does not restore the function once dopaminergic neurons have been damaged, but that it attenuates ongoing neurodegenerative processes. Since PD is a progressive neurodegenerative disorder, the results from experimental animal models would suggest that nicotine might reduce PD progression [219].

V.I.III The Mechanism
Now that it is revealed that there is indeed an inverse relationship between the use of tobacco and PD incidence it is important to know how nicotine is neuroprotective in PD, and what its target(s) are. This knowledge can be used to develop a new therapy with minimum or adverse side effects. 
In general, nicotine exerts its effects in the peripheral and central nervous system by stimulating nicotinic Acetylcholine receptors (nAChr). These are pentameric ligand-gated ion channels composed of α and β subunits or only α subunits [220-225]. The nAChrs in the peripheral nervous system and the brain are distinct from each other, providing an opportunity of selective targeting of the desired receptors. The most relevant nAChrs in the pathophysiology of PD are most likely the ones in the nigrostriatal tract. It has proved quite challenging to identify these nAChrs because multiple subtypes are expressed with six different α- (α2, α3, α4, α5, α6, and α7) and three different β- (β2, β3, β4) subunits in the nigrostriatal pathway. But only selective nAChr subtypes are present in the striatum including the α4β2*, α6β2* and α7 nAChr populations [220-222, 225-226] (the asterisk indicates the possible presence of other subunits in the receptor complex). Evidence for their presence is based on a wide variety of approaches, including work with nAChr-null mutant mice as well as nAChr subtype selective antibodies and lesion studies [220-222, 227]. Recent work has indicated that the α6b2* nAChrs are composed of several subtypes, including the α6α4β2* and α6(non α4)β2* populations [228-229]. Interestingly, these two α6β2* subtypes appear to be differentially regulated with chronic nicotine dosing [230]. A study with nAChr null mutant mice indicated that the α6α4β2* nAChr population may be important for this effect of higher frequency stimulation on dopamine release [230]. The α6α4β2* and α6(non-α4)β2* nAChrs subtypes are not only variably affected by nicotine exposure, but they also appear to be differentially affected by nigrostriatal damage. For instance, the α6α4β2* nAChr subtype is more susceptible to lesions than the α6(non α4)β2* or α4β2* nAChr populations in parkinsonian rodents and monkeys [230]. The data may indicate that the α6α4β2* nAChr subtype is expressed on dopaminergic terminals that are more susceptible to nigrostriatal degeneration. Nicotine-mediated neuroprotection against nigrostriatal damage also appears to involve various nAChr subtypes [231]. The involvement of the α4β2* nAChr subtype is indicated in studies showing a loss of nicotine-mediated protection in α4β2* nAChr knockout mice with nigrostriatal damage [232]. The role of α6β2* nAChr subtypes in neuroprotection is indicated in a study with lesioned rats using the neurotoxin α-conotoxin MII (a-CtxMII) E11A to differentiate between α6α4β2* and α6(non α4)β2* subtypes [231,233]. Receptor competition studies in control and lesioned rats treated with and without nicotine showed that the α6α4β2* subtype is only present when nicotine- mediated protection is observed. This latter subtype may be necessary for neuroprotection and a target for the development of protective strategies against Parkinson’s disease. The mechanisms whereby interaction at α6α4β2* nAChr results in the protection against nigrostriatal damage are not yet known, as the intracellular signalling pathways linked to this specific nAChr subtype are not identified yet. However, based on knowledge of other nAChr subtypes, one might anticipate that changes in multiple downstream pathways are involved, such as alterations in various kinases, including phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB), mitogen-activated protein kinase (MAPK) and jnk kinase, caspases 3, 8 and 9, nitric oxide synthase, the cell survival protein Bcl-2, and other intracellular events [221, 234-235]. Activation of these intracellular messengers may modulate immune responsiveness to enhance neuronal function [236-237]. They may also activate different trophic factors, such as brain-derived neurotrophic factor (BDNF) and/or basic fibroblast growth factor-2 (FGF-2) levels, which are implicated in neuroprotection for nigrostriatal damage [238-240]. Treatment with nAChr ligands directed to these subtypes may thus yield optimal therapeutic benefit for Parkinson’s disease, with a minimum of adverse side effects. 

V.I.IV The influence of nicotine on the gene expression in PD
Genes involved in determining dopamine signalling and disposition have been the focus of many recent epidemiologic studies of Parkinson’s disease (PD). More specifically, polymorphisms in the genes encoding monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) have been explored as potential risk factors for PD. Both MAO-A and MAO-B are located on the X chromosome; their protein products are mitochondrial enzymes that catabolise dopamine, although their sites of expression differ by cell type [241]. The dopamine D2 receptor, an auto-receptor, is encoded by DRD2 (chromosome 11q23), a gene that is also polymorphic and is considered to be a candidate gene in PD as well. Several case-control studies have shown that a single nucleotide polymorphism (SNP) in intron 13 of the MAO-B gene (A→G) substitution 36 bases upstream of exon 14 boundary) is related to PD risk [242]. In a previous study the researchers reported that individuals with the G allele had approximately two times increased risk of PD (OR) =2.09; 95% CI: 1.18–3.69) [243]. Moreover, the inverse relation between smoking and PD was modified by the intron 13 SNP. The protective effect of smoking was limited to subjects with the G allele (OR=0.24 (95% CI: 0.10–0.55)) [244]. These findings have been replicated in an Australian population [245], whereas no interactions were observed in a study of PD in US health professionals [246]. Population-based surveys have indicated that the incidence of PD is considerable higher in men than in women [247]. Kelada et al. (2002) [248] therefore hypothesized that gender might modify the associations among smoking, MAO-B intron 13 genotype, and PD. They tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Y or N allele), and dopamine D2 receptor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson’s disease (PD) cases and 296 age- and gender-matched controls. The odds ratios (ORs) for PD risk for ever smokers versus never smokers were 0.27 (95% CI: 0.13–0.58) for men of genotype G, and 1.26 (0.60–2.63) for men of genotype A (interaction w2 = 8.14, P = 0.004). In contrast, for women, the OR for ever smokers versus never smokers were 0.62 (95% CI: 0.25–1.34) and 0.64 (95% CI: 0.18–2.21) for women of genotype GG/GA and AA, respectively (interaction w2 = 0.001, P=0.975). No interactions were detected between smoking and either MAO-A EcoRV or DRD2 Taq1B genotypes. These results suggest that a strong gender difference exists with respect to the modifying effect of MAO-B genotype on the smoking association with PD. Estrogen and nicotine both have an inhibiting effect on MAO-B, it is possible that estrogen and tobacco smoke constituents interact with MAO-B in different ways to modify PD risk in women. For men, neuroprotection by tobacco smoke constituents varies by MAO-B intron 13 genotype. The overall conclusion is that smoking inhibits MAO-B and therefore act as a neuroprotective factor against PD.
 

V.I.V Nicotine as antioxidant
Yet another hypothesis is that nicotine might provide some of its therapeutic actions in PD and AD through antioxidant mechanisms [249]. 
Initial chromatographic studies suggest that nicotine can affect the formation of the neurotoxin 6-hydroxydopamine resulting from the addition of dopamine to Fenton's reagent (i.e., Fe2+. and H2O2). Thus, under certain circumstances, nicotine can strongly affect the course of the Fenton reaction. In in vivo studies, adult male rats being treated with nicotine showed greater memory retention than controls in a water maze task. However, neurochemical analysis of neocortex, hippocampus, and neostriatum from these same animals revealed that nicotine treatment had no effect on the formation of reactive oxygen species or on lipid peroxidation for any brain region studied. In an in vitro study, addition of various concentrations of nicotine to rat neocortical homogenates had no effect on lipid peroxidation compared to saline controls. The results of these studies suggest that the beneficial/protective effects of nicotine in both Parkinson's disease and Alzheimer's disease may be, at least partly, due to antioxidant mechanisms [249].

V.II Caffeine 
Because cigarette smoking has adverse effects on human health and because it is difficult to determine whether nicotine or other tobacco chemicals may be potentially beneficial in the prevention against Parkinson disease, alternatives are extensively investigated. In contrast, the identification of caffeine as the explanatory molecule for a reduction in the risk of PD among coffee drinkers and the discovery that caffeine reduces the dopaminergic neurotoxicity in PD animal models are promising.

V.II.I Caffeine Reduced PD and the Role of Estrogen
As mentioned earlier the effects of caffeine on the central nervous system are mediated primarily by its antagonistic actions at the A1 and A2A subtypes of adenosine receptors [250]. The action of caffeine on A2A receptors is most likely relevant to PD because the expression of these receptors are only observed in the striatum, and because genetic inactivation of the A2A receptors or selective A2A antagonist , like caffeine , remove the dopaminergic neurotoxicity in animal models of PD [251]. In prospective studies, it is shown that the risk of PD is reduced among men who regularly drank coffee [252-253], whereas in on women such association has not been found yet [252-254]. The gender difference could be explained if the effect of caffeine on risk of PD depends on the levels of estrogen. In a large prospective study on post menopausal women who did not take estrogen replacement therapy there is found a reduced risk of PD [255]. 
In a large cohort study of Ascherio et al. [256] the investigators found that consumption of coffee was associated with a reduced PD mortality among men and among women who never used post menopausal estrogens. On the contrary, PD mortality among women who used estrogen was independent of the consumption of coffee. These results suggest that post menopausal estrogens modify the effects of caffeine on risk of PD. In both men and women a significant reduction in PD risk was present at low levels of caffeine (3-6 cups of coffee a week), and a little further reduction of higher amounts of caffeine intake [256]. The results of this study thus suggest that caffeine reduces the risk of PD but that this may be prevented by the use of estrogen replacement therapy. The results of a MPTP mouse study of Chen et. al. [173] showed that these two agents may work through a common mechanism to prevent MPTP toxicity. Estrogen may compete with caffeine for its activation of a protective pathway. Besides, estrogen and caffeine as well as MPTP share a cytochrome P450, CYP1A2, for their metabolism or detoxification. Therefore, metabolism of caffeine and/or estrogen could alter MPTP metabolism. The effects of estrogen on the risk of PD will be further discussed in the next chapter (III.III).

V.II.II The Mechanism
The detailed mechanisms how caffeine suppresses neuronal death have not been fully understood yet. Nevertheless, in a study of Nakaso et al. [257] Researchers investigated the cytoprotective mechanisms of caffeine using human dopaminergic neuroblastoma SH-SY5Y cells as a PD model. Caffeine prevented the apoptotic cell death that was induced by serum/retinoic acid (RA) deprivation, MPP+, rotenone, and 6-OHDA in SH-SY5Y cells in a dose dependent manner. Caffeine lowered caspase-3 activity induced by serum/RA deprivation and 6-OHDA administration, and also decreased the number of apoptotic condensed and/or fragmented nuclei. Akt (also known as protein kinase B (PKB) was phosphorylated 60 min after caffeine administration in a dose dependent manner; PI3K inhibitors, wortmannin and LY294002 cancelled this cytoprotective effect of caffeine. MAP kinases such as Erk1/2, p38, or JNK on the other hand, were not activated by caffeine. These results suggest that caffeine has a cytoprotective effect due to the suppression of apoptotic signals or the up-regulation of cytoprotective signals. Therefore, the authors investigated the signal transduction pathways in SH-SY5Y cells following caffeine administration and came to the conclusion that caffeine had a cytoprotective effect by the activation of the PI3K/Akt pathways in SH-SY5Y cells. To fully understand the mechanism in which caffeine can help to prevent progression of PD further investigation on this topic is needed.

V.III Estrogen and PD
Experimental, epidemiological, and clinical evidence suggest that female sex hormones may influence the onset and severity of PD symptoms. For instance, PD is more common in men than in women (male to female ratio 3:2) [258]. This ratio suggests that estrogen has a possible protective influence in predisposition of the disease. Gender difference in estrogen levels may also explain why the dopaminergic drugs that are used to treat PD affect men and women differently with regard to therapeutic response, drug clearance, and blood pressure [259-260].
This is supported by several animal studies that have demonstrated estrogenic modulation of pre- and postsynaptic indices of dopaminergic function within the SN and the striatum, as well as estrogens’ ability to protect dopaminergic neurons from MPTP and other toxins. Clinical reports suggest a very potent protective effect of estrogen replacement therapy (ERT) on the onset and the progression of PD and PD-related dementia [261-262].

V.III.I Estrogens and the Nigrostriatal Dopamine System
Estrogen binds to intracellular receptors that enter the nucleus and act as transcription factors to regulate the gene expression [263]. These estrogen receptors were thought not to be expressed in the striatum and SN [264], but recent studies, using more sensitive techniques, report their expression in these regions [265-266]. Adding to the body of evidence is the observation that estrogens may act as well via non-genomic mechanisms such as membrane receptors, and regulation of ion channels [264, 267]. These effects can occur within seconds or minutes; this is too rapid to be caused by the activation of ‘classical’ receptors like the intracellular estrogen receptors [264, 268]. The exact mechanism by which estrogen exert its effects is still not clear but it is evident that estrogen have some profound effects on the functions of dopaminergic neurons in the striatum and SN, which are relevant for the understanding of PD. However, several animal studies with ovariesectomized (OVX) and gonadally intact rats suggest that estrogen alters the function of both presynaptic SN neurons and their postsynaptic targets in the striatum and thereby exerting a potent modulatory influence over dopaminergic transmission within the basal ganglia [269]. However a clear picture of estrogens’ effects has not yet emerged therefore further preclinical research is needed in order to shape the design of future clinical studies of estrogen influences on PD.

V.III.II Neuroprotective Effects of Estrogen in PD Animal Models 

















Chapter VI: Discussion and Future Research Leads

VI.I Conclusion/Discussion
It is still hard to diagnose PD although there are several helpful clues to indicate if patients are dealing with PD or another form of parkinsonism [2]. Besides, patients often not only have the dominating motoric symptoms but also complaints of other non-motoric symptoms that eventually lead to dementia. This can be one of the reasons for misdiagnosis of PD in patients. In PD and Parkinson- plus syndromes the SN neurons will degenerate, and will result in a deficiency of striatal DA concentration [3-7]. The cause of this DA neuron death is not totally clear yet but there are good evidences in different studies that processes like oxidative stress, excitotoxicity, inflammation and loss of neurotrophic factors may have a large influence on this process [8-10]. The combination of neuroinflammation [61-69], exposure to environmental influences (like pesticides) and genetic influences (for example the polymorphisms in genes that function in dopamine signalling pathways) [73-80] appear to be involved in most cases of PD that are sporadic, as mentioned in Chapter II.
Although several epidemiology studies in developed countries, like the study of Leentjens et al. [41] and van den Eeden and co-workers [44], show comparable incidence rates, it is still a crude measurement because of the difference in study methods and misdiagnosis of PD. The differences in the overall incidence between these two studies can be explained by differences in strategy, patient registration and accuracy. Although there are differences in incidence rates between different studies, it is mainly observed that women are less susceptible to PD than men as they show a lower incidence rate, and that this difference is possibly due to the neuroprotective influence of estrogen in PD. This is confirmed by studies with postmenopausal women [255]. 
The difference in PD incidence between different ethnic groups is not confirmed yet [41, 44]. To measure incident rates in developing countries more accurate there should be a better PD database. The prevalence of PD in these countries is however most likely largely underestimated because of misdiagnosis and the lack of competent medics. It is plausible that in developed countries PD is more common than in developing countries as the people in developed countries have a longer average lifespan and better medical care. Besides, in developed countries neurotoxicants like pesticides and MPTP are more widely used and spread because of the industrialisation. In contrast; in developed countries there are more regulations by law on neurotoxicants, so maybe the people here are less exposed. Therefore, studies with geographic variation need to be interpreted with caution, as many factors beyond environmental exposure like migration, chance etc. could determine the geographical pattern of the disease. [44, 52]
While research continues for environmental factors that can be associated with PD, several studies have shown that there are several neuroprotective factors that can be useful in the intervention of PD. These strategies might block or slow degenerative processes of neurons in PD. Potential targets for these neuroprotective factors are events like oxidative stress, mitochondrial dysfunction, excitoxicity and inflammatory changes that lead to apoptotic and necrotic cell death [8-10]. In 2003, the Committee to Identify Neuroprotective Agents in Parkinson’s (CINAPS) published an assessment of potential neuroprotective compounds. Twelve of these compounds where prioritized to be further investigated in clinical trials. Compounds like adenosine receptor antagonists, anti-inflammatory agents, antioxidants, alpha-synuclein blockers, kinase inhibitors and trophic factors have all proven to have a protective effect against PD by blocking or intervention of several degenerative processes and pathways in PD models. However, lack of knowledge of the basics of PD and deficiencies in the methodology used to study disease progression are current barriers. As a result, there are still no convincing outcomes of clinical trials. 
As research on PD continues, the list with potential neuroprotective therapies will grow longer. The most striking is the possible role of nicotine, caffeine and estrogen as neuroprotective agents in PD. Although smoking and the use of other tobacco products is of great risk to human health, treatment with nAChr ligands, other than nicotine, specifically directed to nAChr subtypes may yield optimal therapeutic benefit [219- 240]. Another even more promising neuroprotective agent is caffeine. Caffeine acts agonistically on the A2A receptors and has proven to reduce dopaminergic neurotoxicity in PD animal studies [250-257]. The earlier mentioned neuroprotective factor estrogen not only acts via an antioxidant effect or neurotrophic effect to protect neurons, but has also a possible influence on the neuroprotective characteristics of nicotine and caffeine [258- 276]. Several studies have shown a positive influence of estrogen on the effect of nicotine and caffeine in the neuroprotection against PD. As epidemiological studies already have shown men indeed have a higher risk to develop PD because they lack a physiologically efficient concentration of estrogen for neuroprotection. Based on this knowledge one could conclude that neuroprotective factors act gender specifically, and that each of the specific neuroprotective factors not only can provide a potential new strategy for the protection against PD but also a potential new strategy in combination with each other or with other therapies (like Levopoda therapy). 

As an overall conclusion, based on available literature, neuroprotection in PD remains an important goal that can not be ignored. Successful neuroprotective therapies could turn PD from a progressive and disabling disease to a problem that can be managed. With the rising interest in the understanding and treatment of PD, therapies might improve. In the next paragraph some possible improvements are summarized.

VI.II Future Leads
Now that researchers still find new possible ways of neuroprotection against PD, what can be done or improved with this knowledge in the future? Here are some suggestions:

	The research on neuroprotective factors must be extended to reveal the exact mechanism and possible targets of any neuroprotective factor.
	Better/strict diagnosis of PD patients and other parkinsonian syndromes
	Improvement of education about PD in developing countries 
	Finding other possible neuroprotective factors that are less gender specific
	Finding out the differences in mechanisms of PD in men and PD in women
	Research on the effect of Neuroprotective factors on the genetic pathways and expression of PD.
	Research on the possible restoration effects of neuroprotective factors on degenerated neurons.
	Doing more research on the oxidative and antioxidant properties of nicotine, caffeine and other possible neuroprotective agents.
	Searching for (and maybe creating) other nAChr ligands than nicotine that are of less hazardous to human health.
	Searching for estrogen-like molecules that have the same neuroprotective effect on PD, these molecules can replace estrogen supplements. These new supplements can also provide men protection against PD without the side effects of normal estrogens. This prevention can be useful when men and women have a PD family background or are disposed to certain environmental risk factors like pesticides.
	Because pesticides are widely used in large amounts and because they are possible risk factors on PD, it is of great importance to do more research on the neurotoxicity of pesticides and other neurotoxicants and especially their influence on DA degeneration and so the development of PD. It is known that some pesticides can degenerate DA neurons, but it is often not clear in what amount and at what exposure time. When this is cleared up, maybe scientists can look if neuroprotective factors are a good solution for protection against these neurotoxins;
	And so more research on environmental risk factors for developing PD

These are only suggestions; maybe in the future scientists come up with better suggestions and solutions for research on neuroprotective factors in PD (next paragraph).


VI. III New research plan (??) 

In the previous paragraph improvements on possible new research on neuroprotective factors and PD are summarized. But what kind of experiment would have the most achievable goal and will be relevant to the prevention and understanding of PD? Looking at this thesis the most obvious choice of future research would be research on the three most promising neuroprotective factors; nicotine, caffeine and estrogen. These three compounds have shown to prevent nigrostriatal damage. However, one has to take into account the financial and the ethical aspects. Time and the risk for human health are important to be taken in account as well as the question whether the new experiment will be in vitro or in vivo. In this paragraph the advantages and the disadvantages of possible new research on the three earlier mentioned neuroprotective factors will be discussed.

 It is proven with several epidemiological studies that there is indeed an inverse relationship between tobacco smoke and the incidence of PD [205-214]. Furthermore, several mutant mice experiments have shown that nicotine exerts its neuroprotective effect on nigrostriatal damage via the nAChr receptor [220-225]. But it is also known that smoking cigarettes, or other types of tobacco, is a health hazard and the number one cause of serious chronic disorders and many kinds of cancer. Looking at this ethical issue, is it useful to do further research on the effect of nicotine on PD? 
The answer would still be yes, because besides smoking there is another way to expose experimental subjects to nicotine, namely via nicotine tablets. It is not known if these tablets have any health hazard or that they will have the same effect on nigrostriatal damage as smoking, but it seems a more ethical way. Because nicotine acts via the nAChr receptor it may be possible to do research on other nAChr receptors and its subtypes [227, 231]. In this thesis primarily the in vivo experiments are described. The disadvantage of these in vivo experiments is that knock-out or lesioned animals not necessarily represent the human in vivo PD situation [231-233]. So, it is not clear whether nicotine or other nAChr ligands will have the same effect in humans as in (lesioned) animal models. Hence, extrapolation of the outcome of these experiments to humans who have PD (or have the possibility to develop PD in the future) is tough. Another disadvantage of these in vivo studies is the amount of animals used and also the costs. In vitro experiments would be cheaper but the results will be even harder to extrapolate to humans. Based on the knowledge of other nAChr subtypes, one might anticipate that changes in downstream pathways are involved, and activation of these receptors will result in the activation of intracellular messengers which are involved in neuroprotection for nigrostriatal damage [236-237]. This is however still a speculation, the exact pathway in which nicotine will have any effect on the protection against nigrostriatal damage is still poorly understood. A nice new experiment would therefore be the mapping of these pathways to understand more of the underlying mechanism and other possible advantages and disadvantages of nicotine and/or other nAChr ligands

PD is more common in men than in women [44], this suggests that estrogen has a possible protective effect against nigrostriatal damage. This could be an explanation for the difference in effects of PD treatment in men and women [259-260]. Clinical reports suggest that estrogen have a very potent effect of Estrogen Replacement Therapy (ERT) on the onset and progression of PD [261-262]. As ERT is not available for men, who have a higher risk of developing PD, this is a disadvantage. Normally estrogen binds to intracellular receptor and exerts gene expression in the nucleus. There is however evidence that estrogen can also act via non-genomic mechanisms such as membrane receptors and regulation of ion channels [264, 268]. The exact mechanism by which estrogen exerts its effect is still not clear. Therefore preclinical research on the exact mechanism and pathways of estrogen is needed in order to make a new study design. 
In a MPTP-induced animal model of PD, results showed the interference of estrogen in MPTP uptake and 6-ODHDA into the nigral dopaminergic neurons and alter DA release and uptake [270]. MPTP is used in animal studies because it produces nigrostriatal damage in animal models [271-272]. Although it is known that MPTP might have an acute effect on human health and development of PD [56], one should be careful by making certain statements. Experiments with MPTP do not prove that estrogen is a cure on PD, but more a protection against acute poisoning with MPTP and possible other neurotoxicants [173]. Besides, estrogen has only proven to have an effect on DA damage in animal models and not specifically on PD, therefore the results can not easily be extrapolated to humans.

Because cigarette smoking has serious adverse effects on human health and because it is difficult to determine whether nicotine or other tobacco chemicals may be potentially beneficial in the prevention against PD, less research on nicotine is done. On the contrary, the identification of caffeine as the explanatory molecule for a reduction in the risk of PD is promising.
Caffeine not only has minimal hazardous effects on human health but is also easy and cheap for intake. In prospective studies it is shown that the risk of PD was reduced in man who drank regularly coffee. On women such association has not been found yet. Caffeine exerts its effects via the A2A receptor [250-251]. Estrogen might also bind to this receptor, or act by the same mechanism, to exert its neuroprotective effect. Therefore estrogen might compete with caffeine for its activation of protective pathway. This is, however, never been proved but only assumed by the results of a MPTP mouse study [173]. Again, it is for this reason hard to make the assumption that caffeine and estrogen will act the same in (all) humans and that caffeine and estrogen are specifically protective against PD and not to other neuronal illnesses. The detailed mechanism by which caffeine suppresses neuronal death has not been fully understood yet. Although Nakaso et al. [257] have done in vitro research on the cytoprotective mechanism of caffeine and its signal transduction pathways; it is still not fully clear how caffeine protects against PD progression. 

To conclude, all three neuroprotective factors have advantages as well as disadvantages. Further research is important, but it is clear that it is still a long road to find a cure against PD. Maybe researchers will find a combined therapeutic strategy where nicotine and caffeine (or nicotine and estrogen) can act together against nigrostriatal damage. Or they might find some other compound (maybe by accident) that has neuroprotective properties. 
Untill now the best option to investigate in the future is caffeine; it is cheap, it is not for harmful humans and easy to use in epidemiological studies. Although every human being can act differently on caffeine, it’s is still worth finding out more about the mechanism in which caffeine exerts its neuroprotective effect and what it can mean for people with PD or who are susceptible for PD.  There are not much known hazards of drinking coffee; it  must be certain that drinking a lot of coffee not causing any harm to human health and that the benefits are bigger than the disadvantages. Coffee is known to be neuroprotective in both in vitro and in animal studies, and sometimes it is easier to prevent than to cure. But because PD in humans is hard to detect in before the onset of the symptoms, prevention is of no use. The most important question one should ask in future research is: can caffeine also be neurorestorative. Maybe it is not restorative in vitro or in animal models but maybe in humans it will have different effects. 
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Appendix 1 (Eeden et al. [46])

Incidence/prevalence in Developed Countries (USA)
The United States of America consists of many different race/ ethnicity groups from ‘black’ to ‘whites’ and Asian to Hispanics and is also a well-developed country. It is of this interest to compare data of incidence rates with that of other developing countries like the Netherlands. In contrast with the study in the Netherlands of Leentjens et al. (2003), in the USA study of Van Den Eeden et al. (2003) [46] the authors made a distinction in PD incidence rates between different ethnicities and race within the USA. 

I.III.I Incidence/ prevalence USA 
Before the authors could analyse the incidence rates, the cases of PD had to be defined. The cases were defined as members of KPNCP and were diagnosed with idiopathic PD between January 1, 1994, and December 31, 1995. All cases had to meet modified Core Assessment Program for Intracerebral Transplantation (CAPIT)/Hughes diagnostic criteria at the time of diagnosis and within the study period, according to the following symptoms: 1) the presence of at least two of the following signs: resting tremor, cogwheel rigidity, bradykinesia, and postural reflex impairment, at least one of which must be either resting tremor or bradykinesia; 2) no suggestion of a cause for another Parkinsonian syndrome such as drugs, trauma, brain tumor, or treatment within the last 12 months with dopamine-blocking or dopamine-depleting agents; and 3) no atypical features such as prominent oculomotor palsy, cerebellar signs, vocal cord paresis, severe orthostatic hypotension, pyramidal signs, amyotrophy, or limb apraxia. The base population for this study was the membership of the Kaiser Permanente Medical Care Program (KPMCP), northern California, a large group practice model prepaid health maintenance organization. The authors found the KPMCP data very representative for the general population in gender and race/ethnicity and, because 25-30 percent of the population in these geographical area belonged to the health plan. Besides, according to the Internal survey data the KPMCP membership reflects a broad household income range and is representative for the geographic area except for having a slightly higher education and income level. After defining cases and establishing the study population, the data was collected. Race/ethnicity was categorized as non-Hispanic White, Black, Hispanic, Asian/Pacific Islander, and other. The latter category included Native Americans (n = 3) and unknown (n = 1). When all data was collected the authors statistical analysis was been used. Crude and adjusted annual rates were calculated per 100,000 person-years. Age- and/or gender-adjusted rates and 95 percent confidence intervals were calculated using direct standardization with the age and/or gender distribution of the 1990 US population as the reference population. The results of this study show 588 cases of incident Parkinson disease that met modified Core Asessment Program for Intracerebral Transplantation. The distribution by age, gender, and race/ethnicity for cases and the population at risk is presented in table II. The mean age at diagnosis was 70.5 (range, 38–91) years for men and 70.5 (range, 31–93) years for women. Non-Hispanic Whites were significantly older at diagnosis than either Hispanics or Asian/Pacific Islanders, and they were slightly but not significantly older than Blacks.















































Table II: Nicotine pre-treatment protects against nigrostriatal damage in different parkinsonian animal models.

Table II: Parkinson’s disease cases and population by gender, age, race/ethnicity, and year, Kaiser Permanente, 1994-1995 [46]
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